Research published by Coram shows that helping patients transition to at-home or ambulatory center infusion treatments can be beneficial to both patients and payors. More
Multiple Sclerosis is a $19 billion market worldwide, and the third most expensive specialty drug spend category. Recently approved Ocrevus is likely to add to cost of treatment... More
PAH is a rare, life-threatening disease, which is incurable. It is difficult to manage and to help ensure the longest survival and best possible quality of life, members need... More